EFFECTIVENESS OF SUPERVISED, INTERMITTENT THERAPY FOR TUBERCULOSIS IN HIV-INFECTED PATIENTS

被引:88
作者
ALWOOD, K
KERULY, J
MOORERICE, K
STANTON, DL
CHAULK, CP
CHAISSON, RE
机构
[1] JOHNS HOPKINS UNIV, SCH MED, AIDS SERV, BALTIMORE, MD 21205 USA
[2] BALTIMORE CITY DEPT HLTH, BALTIMORE, MD USA
关键词
HIV; TUBERCULOSIS; DIRECTLY OBSERVED THERAPY; SURVIVAL;
D O I
10.1097/00002030-199408000-00010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To evaluate the effectiveness of supervised therapy for tuberculosis (TB) in patients with HIV infection. Design: Retrospective, chart review. Patients: Patients with TB and HIV infection. Setting: Urban, public TB clinic. Main measures and results: A total of 107 patients with TB and HIV infection were studied. Most were men (78%), African American (91%), uninsured or on Medicaid (88%), and 67% were injecting drug users. TB was diagnosed before AIDS in 31% of subjects, at the time of AIDS in 32%, and after AIDS in 37%. Clinical features varied by stage of HIV disease. Sixteen patients received no therapy and died before TB was diagnosed, 10 died during the first 8 weeks of treatment. Seventy-eight patients received > 8 weeks therapy, of whom 48 (62%) were given directly observed therapy twice weekly and 30 (38%) received self-administered daily therapy. Patients who received directly observed therapy were more likely to complete 6 months of therapy (96 versus 76%, P = 0.02) and more likely to survive after therapy ended (85 versus 57%, P = 0.01). By logistic regression, directly observed therapy, AIDS diagnosed before TB, and age were significantly associated with survival outcome. Conclusion: Directly observed therapy for TB in patients with HIV infection is highly effective and associated with better adherence to therapy and survival.
引用
收藏
页码:1103 / 1108
页数:6
相关论文
共 30 条
[1]  
ALLAN WGL, 1982, TUBERCLE, V63, P89
[2]   2-YEAR INCIDENCE OF TUBERCULOSIS IN COHORTS OF HIV-INFECTED AND UNINFECTED URBAN RWANDAN WOMEN [J].
ALLEN, S ;
BATUNGWANAYO, J ;
KERLIKOWSKE, K ;
LIFSON, AR ;
WOLF, W ;
GRANICH, R ;
TAELMAN, H ;
VANDEPERRE, P ;
SERUFILIRA, A ;
BOGAERTS, J ;
SLUTKIN, G ;
HOPEWELL, PC .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 146 (06) :1439-1444
[3]  
BASS J, 1992, AM REV RESPIR DIS, V146, P1623
[4]  
BASS JB, 1990, AM REV RESPIR DIS, V142, P725
[5]   TUBERCULOSIS - COMMENTARY ON A REEMERGENT KILLER [J].
BLOOM, BR ;
MURRAY, CJL .
SCIENCE, 1992, 257 (5073) :1055-1064
[6]   RESURGENT TUBERCULOSIS IN NEW-YORK-CITY - HUMAN-IMMUNODEFICIENCY-VIRUS, HOMELESSNESS, AND THE DECLINE OF TUBERCULOSIS-CONTROL PROGRAMS [J].
BRUDNEY, K ;
DOBKIN, J .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (04) :745-749
[7]  
CDC, 1993, MMWR-MORBID MORTAL W, V42, P1
[8]   TUBERCULOSIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - CLINICAL-FEATURES, RESPONSE TO THERAPY, AND SURVIVAL [J].
CHAISSON, RE ;
SCHECTER, GF ;
THEUER, CP ;
RUTHERFORD, GW ;
ECHENBERG, DF ;
HOPEWELL, PC .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 136 (03) :570-574
[9]   A 62-DOSE, 6-MONTH THERAPY FOR PULMONARY AND EXTRAPULMONARY TUBERCULOSIS - A TWICE-WEEKLY, DIRECTLY OBSERVED, AND COST-EFFECTIVE REGIMEN [J].
COHN, DL ;
CATLIN, BJ ;
PETERSON, KL ;
JUDSON, FN ;
SBARBARO, JA .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :407-415
[10]   USPHS TUBERCULOSIS SHORT-COURSE CHEMOTHERAPY TRIAL-21 - EFFECTIVENESS, TOXICITY, AND ACCEPTABILITY - THE REPORT OF FINAL RESULTS [J].
COMBS, DL ;
OBRIEN, RJ ;
GEITER, LJ .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :397-406